Form 4: Assertio Holdings Grants Equity to EVP, General Counsel

Assertio Holdings, Inc. granted 18,804 restricted stock units and 21,128 stock options to EVP, General Counsel Sam Schlessinger as part of his compensation.

Summary

• Sam Schlessinger, Executive Vice President and General Counsel of Assertio Holdings, Inc. (ASRT), was granted equity awards.
• The awards include 18,804 Restricted Stock Units (RSUs) and 21,128 Stock Options.
• The transaction date for these grants was March 2, 2026.
• Each RSU represents a contingent right to receive one share of Assertio Holdings' common stock.
• The stock options have an exercise price of $11.77 per share.
• Both the RSUs and stock options were granted without any consideration paid by Mr. Schlessinger.
• One-third of these restricted stock units and stock options are scheduled to vest on each of the first three anniversaries of the grant date, assuming continued employment.
• The RSUs have an expiration date of March 2, 2029, while the stock options expire on March 2, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a routine but positive development, as it aligns executive incentives with long-term shareholder value through equity compensation, which is a standard and effective practice.

Positives

• The equity grants align the interests of EVP, General Counsel Sam Schlessinger with those of shareholders, incentivizing long-term company performance.
• Equity compensation is a standard practice for executive retention and motivation, contributing to management stability.

Negatives

• The future issuance of shares upon vesting and exercise of these awards could lead to a minor dilution of existing shareholder equity.

Risks

• The value of the granted RSUs and stock options is subject to the future market price fluctuations of Assertio Holdings' common stock.
• The awards are contingent on continued employment through the vesting dates, meaning they could be forfeited if employment ceases before full vesting.

Future Outlook

The vesting schedule for the equity awards implies an expectation of continued employment for Sam Schlessinger over the next three years, aligning his long-term incentives with the company's performance.

Management Comments

• The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities.

Industry Context

StockSavvy.ai notes that equity grants, such as restricted stock units and stock options with multi-year vesting, are a common and widely accepted form of executive compensation across the pharmaceutical and biotechnology industries. This practice is designed to align management's financial interests with the long-term performance of the company and shareholder value, while also serving as a key retention tool for senior executives.

Comparison to Industry Standards

• StockSavvy.ai observes that granting RSUs and stock options with multi-year vesting schedules is a standard practice across various industries, including pharmaceuticals, for executive compensation and retention, comparable to practices at companies like Pfizer or Johnson & Johnson for similar roles.
• The structure of the grant, with one-third vesting annually over three years, is a common industry benchmark for incentivizing sustained performance and executive retention.

Related Party Transactions

• The grant of restricted stock units and stock options to Sam Schlessinger, an Executive Vice President and General Counsel, constitutes a related party transaction as it involves compensation to a key management personnel.

Stakeholder Impact

• Shareholders: Potential for future dilution upon vesting and exercise of awards, but also benefit from aligned management incentives for long-term value creation.
• Employees: No direct impact on general employees is mentioned, but it reinforces the company's executive compensation strategy.

Next Steps

• One-third of the granted RSUs and stock options are scheduled to vest on March 2, 2027, March 2, 2028, and March 2, 2029, respectively, contingent on continued employment.

Key Dates

Recommendation

This Form 4 reports a routine equity compensation grant to an executive, which is a standard practice for aligning management incentives. It does not present new information that would fundamentally alter the investment thesis for Assertio Holdings, Inc., thus a 'hold' recommendation is appropriate.

Keywords

Assertio Holdings, ASRT, Sam Schlessinger, Form 4, Restricted Stock Units, Stock Options, Equity Grant, Executive Compensation, Insider Transaction